肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展

程丽珍; 苗雅

doi:10.13406/j.cnki.cyxb.002909

您当前的位置：

首页 >

文章列表页 >

肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展

认知障碍与外周生物标志物关系研究 | 更新时间：2022-06-24

- 肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展
- Research progress of gut microbiota and its metabolites as diagnostic biomarkers of Alzheimer's disease
- 重庆医科大学学报 2021年46卷第11期页码：1352-1354
- 作者机构：
  
  上海交通大学附属第六人民医院老年病科，上海　200235
- 作者简介：
  
  [ "程丽珍，Email：lizcheng1112@163.com，研究方向：认知功能障碍。" ]
  苗雅，副主任医师，医学博士，硕导。上海医学会老年医学专科分会青年委员会副主任委员、中华医学会老年医学分会第十届委员会青年委员、上海市医学会老年医学专科分会第十届委员会神经精神学组委员、《实用老年医学》青年编委会编委、中国老年医学学会认知障碍分会第一届委员会神经心理量表评估学术工作委员会委员、中国女医师协会第一届老年医学专业委员会委员；承担国家自然科学基金、上海市科委自然科学基金及校局级课题多项；在国内外相关期刊发表论文20余篇，其中SCI收录10余篇。Email：nning-my@163.com。
- 基金信息：
  
  上海市自然科学基金资助项目(19ZR1438800)
- DOI：10.13406/j.cnki.cyxb.002909
  中图分类号： R749.16
- 纸质出版日期：2021-11-28，
  
  收稿日期：2021-07-05，
扫描看全文
程丽珍, 苗雅. 肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展[J]. 重庆医科大学学报, 2021,46(11):1352-1354.

Lizhen Cheng, Ya Miao. Research progress of gut microbiota and its metabolites as diagnostic biomarkers of Alzheimer's disease[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1352-1354.
程丽珍, 苗雅. 肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展[J]. 重庆医科大学学报, 2021,46(11):1352-1354. DOI： 10.13406/j.cnki.cyxb.002909.

Lizhen Cheng, Ya Miao. Research progress of gut microbiota and its metabolites as diagnostic biomarkers of Alzheimer's disease[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1352-1354. DOI： 10.13406/j.cnki.cyxb.002909.

摘要

阿尔茨海默病（Alzheimer's disease，AD）是老年期痴呆最常见的一种类型，随着“脑-肠轴”理论的提出，越来越多的研究证实AD的发生发展与肠道菌群构成及其代谢产物的改变密切相关。本文就近年肠道菌群及其代谢产物在AD领域的研究进行综述和讨论，以此为着眼点，阐述以粪便为标本的肠道菌群及其代谢产物检查作为AD诊断生物标志物的应用前景。

Abstract

Alzheimer's disease (AD) is the main cause of senile dementia. With the proposal of the "brain-gut axis" theory

more and more studies have confirmed the occurrence and development of AD are closely related to the change of gut microbiota and its metabolites. This article reviews and discusses the changes of fecal gut microbiota and its metabolites occurred in AD. Besides

the application prospects of fecal gut microbiota and its metabolites as AD diagnostic biomarkers are described.

关键词

阿尔茨海默病肠道菌群生物标志物

Keywords

Alzheimer's diseasegut microbiotabiomarkers

references

Human Microbiome Jumpstart Reference Strains Consortium, Nelson KE, Weinstock GM, et al. A catalog of reference genomes from the human microbiome[J]. Science, 2010, 328(5981):994-999.

Daliri EB, Wei S, Oh DH, et al. The human microbiome and metabolomics: current concepts and applications[J]. Crit Rev Food Sci Nutr, 2017, 57(16):3565-3576.

Pluta R, Januszewski S, Czuczwar SJ. The role of gut microbiota in an ischemic stroke[J]. Int J Mol Sci, 2021, 22(2):E915.

Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype[J]. Mov Disord, 2015, 30(3):350-358.

Ge YS, Wang XH, Guo YL, et al. Gut microbiota influence tumor development and Alter interactions with the human immune system[J]. J Exp Clin Cancer Res, 2021, 40(1):42.

Ticinesi A, Nouvenne A, Tana C, et al. Gut microbiota and microbiota-related metabolites as possible biomarkers of cognitive aging[J]. Adv Exp Med Biol, 2019, 1178:129-154.

Temraz S, Nassar F, Nasr R, et al. Gut microbiome: a promising biomarker for immunotherapy in colorectal cancer[J]. Int J Mol Sci, 2019, 20(17):E4155.

Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study[J]. Lancet Neurol, 2013, 12(4):357-367.

Shen L, Liu L, Ji HF. Alzheimer's disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state[J]. J Alzheimers Dis, 2017, 56(1):385-390.

Bäuerl C, Collado MC, Diaz Cuevas A, et al. Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan[J]. Lett Appl Microbiol, 2018, 66(6):464-471.

Cattaneo A, Cattane N, Galluzzi S, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly[J]. Neurobiol Aging, 2017, 49:60-68.

Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer's disease[J]. Sci Rep, 2017, 7(1):13537.

Zhuang ZQ, Shen LL, Li WW, et al. Gut microbiota is altered in patients with Alzheimer's disease[J]. J Alzheimers Dis, 2018, 63(4):1337-1346.

Haran JP, Bhattarai SK, Foley SE, et al. Alzheimer's disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway[J]. mBio, 2019, 10(3):e00619-e00632.

Liu P, Wu L, Peng GP, et al. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort[J]. Brain Behav Immun, 2019, 80:633-643.

Li BY, He YX, Ma JF, et al. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota[J]. Alzheimers Dement, 2019, 15(10):1357-1366.

Zhang L, Wang Y, Xiayu X, et al. Altered gut microbiota in a mouse model of Alzheimer's disease[J]. J Alzheimers Dis, 2017, 60(4):1241-1257.

Yuan BF, Zhu QF, Guo N, et al. Comprehensive profiling of fecal metabolome of mice by integrated chemical isotope labeling-mass spectrometry analysis[J]. Anal Chem, 2018, 90(5):3512-3520.

Zheng J, Zheng SJ, Cai WJ, et al. Stable isotope labeling combined with liquid chromatography-tandem mass spectrometry for comprehensive analysis of short-chain fatty acids[J]. Anal Chim Acta, 2019, 1070:51-59.

Wu L, Han YQ, Zheng ZP, et al. Altered gut microbial metabolites in amnestic mild cognitive impairment and Alzheimer's disease: signals in host-microbe interplay[J]. Nutrients, 2021, 13(1):228.

Bibbò S, Ianiro G, Giorgio V, et al. The role of diet on gut microbiota composition[J]. Eur Rev Med Pharmacol Sci, 2016, 20(22):4742-4749.

Wang XY, Sun GQ, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression[J]. Cell Res, 2019, 29(10):787-803.

Xiao SF, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia[J]. Alzheimers Res Ther, 2021, 13(1):62.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究

胰腺导管腺癌免疫检查点阻断耐药的生物标志物和治疗选择

生物信息学联合机器学习探究主动脉瓣膜钙化潜在的诊断标志物

肠菌移植治疗炎症性肠病14例临床观察

铁死亡在阿尔茨海默病中的研究进展